Physician profile
Reena S Sampat
NPI 1104112184
$3,255.68
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $919 · 2022: $1,195 · 2023: $1,077 · 2024: $65.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $722.54 | 2021-2024 | Dupixent |
| Incyte Corporation | $402.96 | 2021-2023 | Opzelura |
| Sun Pharmaceutical Industries INC. | $390.70 | 2021-2023 | Blu-U |
| Pfizer INC. | $380.56 | 2021-2023 | |
| Abbvie INC. | $374.97 | 2021-2023 | |
| Genzyme Corporation | $212.74 | 2021-2022 | |
| Leo Pharma INC. | $146.58 | 2021-2023 | Adbry |
| Janssen Biotech, INC. | $134.60 | 2021-2023 | Stelara, Remicade, Simponi Aria |
| Biofrontera INC. | $116.62 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Novartis Pharmaceuticals Corporation | $103.95 | 2022-2023 | |
| Lilly USA, LLC | $82.92 | 2021 | |
| Mayne Pharma Commercial LLC | $46.90 | 2023 | |
| Journey Medical Corporation | $45.01 | 2022 | |
| Vyne Pharmaceuticals INC. | $26.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.32 | 2023 | Sotyktu |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $21.11 | 2021 | |
| Almirall LLC | $20.70 | 2023 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Sampat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.